Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant nab-paclitaxel + gemcitabine in pancreatic cancer surgery
ChiCTR2100042599Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of paclitaxel and gemcitabine in pancreatic cancer (PC) (3 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: R0 resection rate. Started Feb 2021; status: recruiting.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2100042599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042599.